Digoxin Mechanism: Stronger Contraction, Slower AV Conduction
How does digoxin strengthen contraction and slow AV conduction?
Digoxin inhibits sodium-potassium ATPase, increasing intracellular sodium and calcium availability in cardiac cells. That supports contraction. Its parasympathetic effects also slow AV-node conduction. These are different actions within one drug’s response; neither makes digoxin a routine first choice for every patient with atrial fibrillation or heart failure.
Key takeaways
- Na-K ATPase inhibition and AV-node slowing are different parts of the mechanism.
- More calcium availability supports contraction without guaranteeing a favorable overall outcome.
- Renal function and electrolyte abnormalities matter to toxicity risk.
How does the sodium-potassium pump affect calcium?
Inhibiting Na-K ATPase changes the sodium gradient across the cell membrane. Increased intracellular sodium reduces calcium extrusion through the sodium-calcium exchanger, helping increase calcium available for contraction.
This is an introductory explanation of an interacting system, not a claim that digoxin directly binds the exchanger. The cited experimental work concerns the mechanism and does not establish a clinical dosing or outcome rule.
Why can AV conduction slow at the same time?
Digoxin’s parasympathetic effects increase vagal influence and slow conduction through the AV node. That nodal effect can coexist with an increase in myocardial contractility.
The result depends on the rhythm and patient. Digoxin does not simply slow every possible rhythm, and toxicity can produce different arrhythmias. Its role in selected atrial fibrillation and heart-failure settings requires the broader clinical context.
Why is the therapeutic margin important?
Digoxin has a narrow therapeutic index. Renal impairment, low potassium or magnesium, and interacting medicines can increase toxicity concerns. A concentration also needs appropriate timing and interpretation with symptoms and rhythm.
Do not turn one laboratory value into an absolute safe-or-toxic boundary. This page explains the mechanism; it does not prescribe a dose or decide whether a particular patient should receive digoxin.
